Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026)
Avalo Therapeutics posted quarterly Retained Earnings of -$468.2 million for Q1 2026, down 22.1% year-on-year from -$601.0 million in Q1 2025, and down 4.38% on a QoQ basis from -$448.5 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Retained Earnings data on file, last reported at -$468.2 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 22.1% year-over-year to -$468.2 million; the trailing twelve-month figure through Mar 2026 stood at -$468.2 million (down 22.1% YoY), and the FY2025 full-year result was -$448.5 million, changed N/A from the prior year.
- Retained Earnings for Q1 2026 stood at -$468.2 million, down from -$448.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$34000.0 in Q2 2025 and bottomed at -$468.2 million in Q1 2026.
- The 5-year median for Retained Earnings is -$330.9 million (2023), against an average of -$335.1 million.
- The widest annual swing landed in 2024, when Retained Earnings slumped 45.45%; it then surged 99.99% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$303.8 million in 2022, then retreated by 10.31% to -$335.1 million in 2023, then climbed by 0.06% to -$334.9 million in 2024, then plunged by 33.92% to -$448.5 million in 2025, then fell by 4.38% to -$468.2 million in 2026.
- The last three Retained Earnings figures came in at -$468.2 million (Q1 2026), -$448.5 million (Q4 2025), and -$434.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -468.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -468.15 Mn |
| Dec 31, 2025 | -448.52 Mn |
| Sep 30, 2025 | -434.80 Mn |
| Jun 30, 2025 | -34,000.00 |
| Mar 31, 2025 | -383.41 Mn |
| Sep 30, 2024 | -334.92 Mn |
| Jun 30, 2024 | -357.96 Mn |
| Mar 31, 2024 | -456.42 Mn |
| Dec 31, 2023 | -335.13 Mn |
| Sep 30, 2023 | -326.97 Mn |
| Jun 30, 2023 | -321.74 Mn |
| Mar 31, 2023 | -313.80 Mn |
| Dec 31, 2022 | -303.82 Mn |
| Sep 30, 2022 | -294.01 Mn |
| Jun 30, 2022 | -297.20 Mn |
| Mar 31, 2022 | -284.22 Mn |
| Dec 31, 2021 | -262.17 Mn |
| Sep 30, 2021 | -243.00 Mn |
| Jun 30, 2021 | -225.58 Mn |
| Mar 31, 2021 | -208.50 Mn |
| Dec 31, 2020 | -177.79 Mn |
| Sep 30, 2020 | -162.10 Mn |
| Jun 30, 2020 | -148.69 Mn |
| Mar 31, 2020 | -135.41 Mn |
| Dec 31, 2019 | -114.29 Mn |
| Sep 30, 2019 | -115.90 Mn |
| Jun 30, 2019 | -111.90 Mn |
| Mar 31, 2019 | -105.70 Mn |
| Dec 31, 2018 | -98.22 Mn |
| Sep 30, 2018 | -92.66 Mn |
| Jun 30, 2018 | -68.10 Mn |
| Mar 31, 2018 | -62.00 Mn |
| Dec 31, 2017 | -58.17 Mn |
| Sep 30, 2017 | -55.07 Mn |
| Jun 30, 2017 | -73.79 Mn |
| Mar 31, 2017 | -72.00 Mn |
| Dec 31, 2016 | -70.04 Mn |
| Sep 30, 2016 | -68.40 Mn |
| Jun 30, 2016 | -62.23 Mn |
| Mar 31, 2016 | -58.70 Mn |
| Dec 31, 2015 | -53.56 Mn |
| Sep 30, 2015 | -49.91 Mn |
| Dec 31, 2014 | -43.07 Mn |